Notice of AGM

Silence Therapeutics Notice of Annual General Meeting

May 7, 2020

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that this year's Annual General Meeting ("AGM") of the Company will be held on 9 June 2020 at 10:00am. The AGM will be held at Herons Ghyll, Tilford Road, Tilford, Surrey GU10 2DD.

The Notice of the AGM will be posted to shareholders today, 7 May 2020, when it will also be made available on the Company's website.

To comply with the UK Government's Stay at Home measures, shareholders will not be allowed to attend the meeting in person. Shareholders are strongly encouraged to therefore submit their votes, in respect of all matters of business, via proxy as early as possible. They should appoint the Chairman of the meeting as their proxy. If the situation changes then shareholders will be notified via the Company's website at https://www.silence-therapeutics.com and via RNS announcement.

Enquiries:

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/